DeLLphi-305 raises a real-world challenge:

CRS occurred in 49.6% with tarlatamab + durvalumab, although grade ≥3 CRS was only 0.4%. ICANS: 1.1%.

Can community oncology safely deliver this regimen?

Monitoring, resources and patient access will be critical. #ESMO26